Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

They said a device that stimulates the vagus nerve in the neck while simultaneously playing different sounds for several weeks helped eliminate the condition in a group of rats. A trial of the treatment in humans is set to start in Europe this year, said Dr. Navzer Engineer of MicroTransponder, a medical device company affiliated with The University of Texas at Dallas, whose study appears in the journal Nature. Tinnitus is sometimes brought on by hearing loss. It occurs as cells in the inner ear are damaged, often from a loud noise. Current drugs help mask tinnitus, but the condition is incurable. Engineer’s team thinks tinnitus may be caused when too many brain cells become tuned to a specific tone in the brain. So his team set out to train the brain to ignore the nerve signals that cause the ringing sound. To do this, they paired a device that sends electrical impulses to the vagus nerve in the neck with different sounds. Stimulating this nerve releases chemicals such as acetylcholine and norepinephrine that trigger changes in the brain. The University of Texas at Dallas team tested this approach in a series of experiments with rats, using an indirect but accepted method of testing hearing in animals. In one, they stimulated the vagus nerve while playing different sounds 300 times a day for 20 days to a group of eight rats with a form of tinnitus. The tones were close to the frequency of the ringing sound, and the hope was to trick some of the nerve cells into listening to the new tones rather than the ringing tone. When the team checked the nerve responses to different tones, the tinnitus had disappeared in rats exposed to the tones and nerve stimulation, but it persisted in a group of control animals. “Unlike previous treatments, we’re not masking the tinnitus. We are eliminating the source of the tinnitus,” Michael Kilgard of the University of Texas-Dallas, who worked on the study, said in a statement. MicroTransponder is developing a wireless medical device to stimulate the vagus nerve and hopes to test it in people later this year. Cyberonics Inc already sells vagus nerve stimulation devices for people with epilepsy and depression. The National Institute on Deafness and Other Communication Disorders, part of the National Institutes of Health, funded a large part of the research.
Device treatment may silence ringing in the ears.

The company has since mid-March launched three coronavirus tests, including an antibody test crucial in identifying immunity among people and one that can deliver results within minutes, which was heralded as a game changer by President Donald Trump. Shares of the company were up 6% at $96.48 in morning trading. Despite the strong uptake in coronavirus testing, the cancellation of non-essential surgeries and restrictions on people’s movement are expected to severely crimp sales of its medical devices and other lab tests, which contribute to more than half of total quarterly revenue. “(The second quarter) will likely be our toughest quarter in the year, especially for our core lab business, our cardio and neuro businesses,” Chief Executive Officer Robert Ford said on a post-earnings call. The company suspended its full-year forecast due to the uncertainty caused by the health crisis and said it expects to provide an update in the second half of the year. Abbott projected a recovery in elective procedures and testing volumes globally from the third quarter and said it was seeing signs of stabilization in China and areas where the outbreak has begun to abate. “We’re all hoping for a fast recovery here, but if it takes longer, we’ll have strong demand for testing and that will continue to help buffer the impact,” Ford said. Elective procedure declines were at the core of Johnson & Johnson’s (JNJ.N) decision to cut 2020 forecasts on Tuesday, with recovery expected in the second half of the year. Abbott beat first-quarter earnings expectations as shelter-in-place restrictions imposed by U.S. states boosted demand for nutrition products for children such as PediaSure, lifting sales in the unit by 6.3% to $1.90 billion. Results were also boosted by a strong flu season before the outbreak that helped minimize testing declines and on softer-than-expected COVID-19 impact across businesses, said J.P. Morgan analyst Robbie Marcus. Sales in the diagnostics unit fell nearly 1% to $1.83 billion, while demand for its FreeStyle Libre diabetes monitoring device remained strong fueled by expanded insurance coverage in Japan. Sales of the device surged 60% to over $600 million. Excluding items, the company earned 65 cents per share, beating expectation of 58 cents. Net sales of $7.73 billion also topped estimates of $7.34 billion.
Coronavirus test ramp-up to help Abbott weather 'toughest quarter'.

Licenses for hemp cultivation topped a half-million acres (200,000 hectares) last year, more than 450% above 2018 levels, so there’s intense interest in the rules the U.S. government is creating. Critical comments on the draft have poured in from hemp farmers, processors, retailers and state governments. Growers are concerned the government wants to use a heavy hand that could result in many crops failing required tests and being destroyed. The U.S. Department of Agriculture, the agency writing the rules, estimates 20% of hemp lots would fail under the proposed regulations. “Their business is to support farmers — and not punish farmers — and the rules as they’re written right now punish farmers,” said Dove Oldham, who last year grew an acre (0.40 hectares) of hemp on her family farm in Grants Pass. “There’s just a lot of confusion, and people are just looking for leadership.” The USDA did not respond to the criticism but has taken the unusual step of extending the public comment period by a month, until Jan. 29. The agency told The Associated Press it will analyze information from this year’s growing season before releasing its final rules, which would take effect in 2021. Agricultural officials in states that run pilot hemp cultivation programs under an earlier federal provision are weighing in with formal letters to the USDA. “There are 46 states where hemp is legal, and I’m going to say that every single state has raised concerns to us about something within the rule. They might be coming from different perspectives, but every state has raised concerns,” said Aline DeLucia, director of public policy for the National Association of State Departments of Agriculture. Most of the anxiety involves how the federal government plans to test for THC, the high-inducing compound found in marijuana and hemp, both cannabis plants. The federal government and most states consider plants with tiny amounts — 0.3% or less — to be hemp. Anything above that is marijuana and illegal under federal law. Yet another cannabis compound has fueled the explosion in hemp cultivation. Cannabidiol, or CBD, is marketed as a health and wellness aid and infused in everything from food and drinks to lotions, toothpaste and pet treats. Many have credited CBD with helping ease pain, increase sleep and reduce anxiety. But scientists caution not enough is known about its health effects, and the U.S. Food and Drug Administration last year targeted nearly two dozen companies for making CBD health claims. Still, the CBD market is increasing at a triple-digit rate and could have $20 billion in sales by 2024, according to a recent study by BDS Analytics, a marketing analysis firm that tracks cannabis industry trends. About 80% of the 18,000 farmers licensed for hemp cultivation are in the CBD market, said Eric Steenstra, president of the advocacy group Vote Hemp. The remaining 20% grow hemp for its fiber, used in everything from fabric to construction materials, or its grain, which is added to health foods. But hemp is a notoriously fickle crop. Conditions such as sunlight, moisture and soil composition determine its ratio of THC to CBD. Choosing the right harvesting window is critical to ensuring it stays within acceptable THC levels. Under the draft USDA rules, farmers have no wiggle room. They must harvest within 15 days of testing their crop for THC, and the samples must be sent to a lab certified by the U.S. Drug Enforcement Administration. Samples must be from the top of the plant, where THC levels are highest, and the final measurement must include not just THC, but also THCA, a nonpsychoactive component. Crops that test above 0.3% for the two combined must be destroyed. Growers with crops above 0.5% would be considered in “negligent violation,” and those with repeated violations could be suspended from farming hemp. In addition, a pilot program for federal crop insurance that would be available to hemp growers in some states specifies that crops lost because of high THC levels won’t be covered. Those provisions are causing alarm among growers and states with pilot hemp programs allowed under the 2014 Farm Bill. Some states allow THC levels above 0.3%, and not all include THCA in that calculation. Many permit more harvesting time for growers after THC testing. Farmers are lobbying for a 1% THC limit and a 30-day harvest window to give them more flexibility while remaining well under THC levels that can get people high. The draft regulations don’t “seem to be informed by the reality of the crop,” said Jesse Richardson, who with his brother sells CBD-infused teas and capsules under the brand The Brothers Apothecary. “If no one can produce (federally) compliant hemp flower, then there will be no CBD oil on the market.” Growers are also worried about the proposed rule requiring that all THC testing be done in a DEA-certified lab because there are so few of them. Some states have only one, which would serve hundreds of growers in a short harvest window. Samantha Ford, a third-generation farmer in North Carolina, waited two weeks to get back THC results from a lab last fall and then spent 45 days harvesting her 1 acre (0.40 hectares) of hemp by hand. “The 15-day window — that’s not feasible, and that was on a small scale,” she said. “I can’t imagine farmers who have acres and acres and acres of it.” Concerns also have emerged about the workload the draft rules would place on states. Many do random sampling for THC levels, but the USDA would require five samples from every hemp lot — a burden for state agricultural departments, said DeLucia, of the national ag agencies group. If federal rules are too onerous and expensive, some states might drop their hemp programs. In those cases, farmers would have to apply for licenses with the USDA, and at this stage it’s unclear how U.S. officials would manage or pay for a nationwide licensing program, DeLucia said. Under the 2018 Farm Bill, the USDA must approve state plans for hemp programs. Louisiana, Ohio and New Jersey last month were the first to get the green light — but those plans might need to be reworked after final rules are written. “What we don’t want to see is states having to write their rules and then have to change the rules again and rewrite them” after 2021, said Steenstra, of Vote Hemp.

High anxiety: Proposed US hemp rules worry industry .